NASDAQ: SIBNSi Bone Inc Stock
$24.27-0.27 (-1.1%)
Updated May 26, 2023
SIBN Price
$24.27
Fair Value Price
$25.15
Market Cap
$853.92M
52 Week Low
$11.14
52 Week High
$27.24
P/E
-15.26x
P/B
9.09x
P/S
5.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$116.68M
Earnings
-$54.97M
Gross Margin
84%
Operating Margin
-44.46%
Profit Margin
-47.1%
Debt to Equity
0.59
Operating Cash Flow
-$39M
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SIBN Overview
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SIBN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SIBN ($24.27) is undervalued by 3.48% relative to our estimate of its Fair Value price of $25.15 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SIBN ($24.27) is not significantly undervalued (3.48%) relative to our estimate of its Fair Value price of $25.15 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SIBN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SIBN due diligence checks available for Premium users.
Be the first to know about important SIBN news, forecast changes, insider trades & much more!
SIBN News
Valuation
SIBN fair value
Fair Value of SIBN stock based on Discounted Cash Flow (DCF)
Price
$24.27
Fair Value
$25.15
Undervalued by
3.48%
SIBN ($24.27) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SIBN ($24.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SIBN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SIBN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-15.26x
Industry
751.36x
Market
54.23x
SIBN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.09x
Industry
3.87x
SIBN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SIBN's financial health
Profit margin
Revenue
$32.7M
Net Income
-$11.1M
Profit Margin
-34%
SIBN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SIBN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$149.1M
Liabilities
$55.1M
Debt to equity
0.59
SIBN's short-term assets ($128.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SIBN's short-term assets ($128.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SIBN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.8M
Investing
$11.7M
Financing
$1.2M
SIBN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SIBN vs Medical Device Stocks
Si Bone Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.